期刊
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY
卷 13, 期 -, 页码 3627-3635出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DMSO.S265399
关键词
diabetes mellitus; hypertension; peroxisome proliferator-activated receptors; telmisartan
Telmisartan is an angiotensin II receptor antagonist, which selectively inhibits the angiotensin II type 1 receptor. Thus, it is widely used for hypertension management. Nowadays, telmisartan's effect on peroxisome proliferator-activated receptors (PPARs) is gaining wider attention. PPARs are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Telmisartan is reported to have a partial PPAR gamma-agonistic effect while avoiding the safety concerns found with full PPAR gamma agonists (thiazolidinediones). Telmisartan could be an alternative treatment option, with dual benefit for diabetes mellitus (DM) and hypertension. This review summarizes the anti-diabetic activity of telmisartan via its partial PPAR gamma-agonistic activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据